FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

Off Science and Research

Dateline City:
KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.

Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Radiation

Under New FDA-Initiated Program, Combination Treatment Is the First to Receive Simultaneous Review Decisions in the U.S., Australia and Canada

KENILWORTH, N.J., & WOODCLIFF LAKE, N.J.–(BUSINESS WIRE)–Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the U.S.

Language:
English

Contact:

Merck Media Relations
Pamela Eisele: (267) 305-3558
Kristen Drake: (908) 334-4688

Merck Investor Relations
Michael DeCarbo: (908) 740-180

Eisai Inc. Media Relations
Michele Randazzo: (201) 746-297

Ticker Slug:
Ticker:
MRK

Exchange:
NYSE

@Merck

read more

Read Original Article: FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma »

About The Author